RxDoctor Payments Data

Haley Haught

Family · Delhi, LANPI 1114280633

Payments from drug & device makers

$5,449in general payments, 2019–2025

Across 308 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$638
  • AstraZeneca$504
  • Bayer$498
  • Novo Nordisk$436
  • Novartis$430
  • Lilly USA, LLC$389
  • plus $3K from 26 others

What the payments were for

  • Food & beverage$5,449100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,449 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$36,699
KerendiaFinerenone24$28,257
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$26,628
TrulicityDulaglutide18$26,614
LinzessLinaclotide38$24,338
FarxigaDapagliflozin Propanediol24$19,385
EliquisApixaban16$18,487
RybelsusSemaglutide17$16,243
MounjaroTirzepatide13$15,507
TradjentaLinagliptin17$14,510
JanuviaSitagliptin Phosphate16$13,874
XareltoRivaroxaban17$13,252
VascepaIcosapent Ethyl25$10,305
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$6,493
Albuterol Sulfate HfaAlbuterol Sulfate43$1,737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$436$52,94245 claims
Lilly USA, LLCTrulicity, Mounjaro$389$42,12131 claims
BayerKerendia$498$28,25724 claims
GSKTrelegy Ellipta$340$26,62820 claims
AbbVieLinzess$257$24,33838 claims
AstraZenecaFarxiga$504$19,38524 claims
PfizerEliquis$102$18,48716 claims
Boehringer IngelheimTradjenta$197$14,51017 claims
MerckJanuvia$232$13,87416 claims
Johnson & JohnsonXarelto$23$13,25217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.

Other family in Delhi

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →